NASDAQ:ZNTL

Zentalis Pharmaceuticals Competitors

$50.68
+0.40 (+0.80 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$48.01
Now: $50.68
$52.50
50-Day Range
$37.41
MA: $43.03
$50.85
52-Week Range
$23.50
Now: $50.68
$61.29
Volume331,133 shs
Average Volume290,969 shs
Market Capitalization$2.08 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Vs. BBIO, MRTX, RARE, ARWR, GWPH, and ASND

Should you be buying ZNTL stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Zentalis Pharmaceuticals, including BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), and Ascendis Pharma A/S (ASND).

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Valuation and Earnings

This table compares Zentalis Pharmaceuticals and BridgeBio Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zentalis PharmaceuticalsN/AN/AN/AN/AN/A
BridgeBio Pharma$40.56 million201.80$-260,590,000.00($2.48)-22.16

Zentalis Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma.

Profitability

This table compares Zentalis Pharmaceuticals and BridgeBio Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zentalis PharmaceuticalsN/AN/AN/A
BridgeBio PharmaN/A-109.88%-48.54%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Zentalis Pharmaceuticals and BridgeBio Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zentalis Pharmaceuticals00703.00
BridgeBio Pharma01902.90

Zentalis Pharmaceuticals currently has a consensus target price of $56.4286, indicating a potential upside of 14.93%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Zentalis Pharmaceuticals.

Institutional & Insider Ownership

67.1% of Zentalis Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are owned by institutional investors. 40.3% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

BridgeBio Pharma beats Zentalis Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Valuation and Earnings

This table compares Zentalis Pharmaceuticals and Mirati Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zentalis PharmaceuticalsN/AN/AN/AN/AN/A
Mirati Therapeutics$3.34 million2,398.14$-213,260,000.00($5.69)-27.80

Zentalis Pharmaceuticals has higher earnings, but lower revenue than Mirati Therapeutics.

Profitability

This table compares Zentalis Pharmaceuticals and Mirati Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zentalis PharmaceuticalsN/AN/AN/A
Mirati TherapeuticsN/A-60.01%-54.21%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Zentalis Pharmaceuticals and Mirati Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zentalis Pharmaceuticals00703.00
Mirati Therapeutics151002.56

Zentalis Pharmaceuticals currently has a consensus target price of $56.4286, indicating a potential upside of 14.93%. Mirati Therapeutics has a consensus target price of $218.5714, indicating a potential upside of 37.21%. Given Mirati Therapeutics' higher possible upside, analysts plainly believe Mirati Therapeutics is more favorable than Zentalis Pharmaceuticals.

Institutional & Insider Ownership

67.1% of Zentalis Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.9% of Mirati Therapeutics shares are owned by institutional investors. 4.1% of Mirati Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Mirati Therapeutics beats Zentalis Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Valuation and Earnings

This table compares Zentalis Pharmaceuticals and Ultragenyx Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zentalis PharmaceuticalsN/AN/AN/AN/AN/A
Ultragenyx Pharmaceutical$103.71 million70.18$-402,730,000.00($7.36)-14.77

Zentalis Pharmaceuticals has higher earnings, but lower revenue than Ultragenyx Pharmaceutical.

Profitability

This table compares Zentalis Pharmaceuticals and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zentalis PharmaceuticalsN/AN/AN/A
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Zentalis Pharmaceuticals and Ultragenyx Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zentalis Pharmaceuticals00703.00
Ultragenyx Pharmaceutical06802.57

Zentalis Pharmaceuticals currently has a consensus target price of $56.4286, indicating a potential upside of 14.93%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, indicating a potential upside of 20.73%. Given Ultragenyx Pharmaceutical's higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Zentalis Pharmaceuticals.

Institutional & Insider Ownership

67.1% of Zentalis Pharmaceuticals shares are owned by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Zentalis Pharmaceuticals beats Ultragenyx Pharmaceutical on 5 of the 9 factors compared between the two stocks.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Valuation and Earnings

This table compares Zentalis Pharmaceuticals and Arrowhead Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zentalis PharmaceuticalsN/AN/AN/AN/AN/A
Arrowhead Pharmaceuticals$87.99 million79.80$-84,550,000.00($0.84)-80.54

Zentalis Pharmaceuticals has higher earnings, but lower revenue than Arrowhead Pharmaceuticals.

Profitability

This table compares Zentalis Pharmaceuticals and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zentalis PharmaceuticalsN/AN/AN/A
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Zentalis Pharmaceuticals and Arrowhead Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zentalis Pharmaceuticals00703.00
Arrowhead Pharmaceuticals021002.83

Zentalis Pharmaceuticals currently has a consensus target price of $56.4286, indicating a potential upside of 14.93%. Arrowhead Pharmaceuticals has a consensus target price of $85.3077, indicating a potential upside of 26.27%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Zentalis Pharmaceuticals.

Institutional & Insider Ownership

67.1% of Zentalis Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Zentalis Pharmaceuticals beats Arrowhead Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and GW Pharmaceuticals (NASDAQ:GWPH) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Valuation and Earnings

This table compares Zentalis Pharmaceuticals and GW Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zentalis PharmaceuticalsN/AN/AN/AN/AN/A
GW Pharmaceuticals$311.33 million22.04$-9,020,000.00($0.24)-912.08

Zentalis Pharmaceuticals has higher earnings, but lower revenue than GW Pharmaceuticals.

Profitability

This table compares Zentalis Pharmaceuticals and GW Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zentalis PharmaceuticalsN/AN/AN/A
GW Pharmaceuticals-11.05%-7.46%-6.13%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Zentalis Pharmaceuticals and GW Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zentalis Pharmaceuticals00703.00
GW Pharmaceuticals010402.29

Zentalis Pharmaceuticals currently has a consensus target price of $56.4286, indicating a potential upside of 14.93%. GW Pharmaceuticals has a consensus target price of $204.0909, indicating a potential downside of 6.69%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Zentalis Pharmaceuticals is more favorable than GW Pharmaceuticals.

Institutional & Insider Ownership

67.1% of Zentalis Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are owned by institutional investors. 3.1% of GW Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Zentalis Pharmaceuticals beats GW Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings.

Earnings & Valuation

This table compares Zentalis Pharmaceuticals and Ascendis Pharma A/S's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zentalis PharmaceuticalsN/AN/AN/AN/AN/A
Ascendis Pharma A/S$14.98 million437.57$-244,180,000.00($5.25)-23.23

Zentalis Pharmaceuticals has higher earnings, but lower revenue than Ascendis Pharma A/S.

Profitability

This table compares Zentalis Pharmaceuticals and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zentalis PharmaceuticalsN/AN/AN/A
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Zentalis Pharmaceuticals and Ascendis Pharma A/S, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zentalis Pharmaceuticals00703.00
Ascendis Pharma A/S011102.92

Zentalis Pharmaceuticals presently has a consensus price target of $56.4286, indicating a potential upside of 14.93%. Ascendis Pharma A/S has a consensus price target of $187.6667, indicating a potential upside of 52.69%. Given Ascendis Pharma A/S's higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Zentalis Pharmaceuticals.

Institutional and Insider Ownership

67.1% of Zentalis Pharmaceuticals shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Zentalis Pharmaceuticals beats Ascendis Pharma A/S on 5 of the 9 factors compared between the two stocks.


Zentalis Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.95+1.5%$8.19 billion$40.56 million-16.11
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$158.19+3.7%$8.01 billion$3.34 million-20.54News Coverage
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$108.72+0.8%$7.28 billion$103.71 million-24.77Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.65+0.5%$7.02 billion$87.99 million-80.54News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.90+0.0%$6.86 billion$311.33 million-127.27Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$121.95+1.8%$6.55 billion$14.98 million-14.85Analyst Downgrade
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.78+2.3%$6.30 billion$150,000.00-21.12Unusual Options Activity
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78+0.6%$5.74 billion$1.12 billion84.96
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.80+1.2%$5.70 billion$380.83 million-9.18Analyst Report
Perrigo logo
PRGO
Perrigo
2.3$41.62+1.1%$5.56 billion$4.84 billion-693.55
Allakos logo
ALLK
Allakos
1.7$104.50+3.5%$5.55 billionN/A-38.14Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.20+0.8%$5.52 billion$66.51 million17.56Analyst Report
Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.3$78.18+0.2%$5.49 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.15+0.3%$5.19 billion$1.00 billion-11.99Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.40+1.9%$4.62 billionN/A-6.06Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.13+0.8%$4.41 billion$6.87 million-7.36Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.25+0.4%$4.26 billion$204.89 million-36.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64+4.1%$4.16 billion$1.11 billion24.96Analyst Report
I-Mab logo
IMAB
I-Mab
1.2$57.00+0.2%$4.10 billion$4.31 million-1.97Increase in Short Interest
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90+3.2%$3.98 billion$806.43 million-9.33Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.69+0.6%$3.82 billion$117.91 million-11.09
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.94+2.4%$3.72 billionN/A0.00Analyst Report
Increase in Short Interest
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57+1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03+5.8%$3.58 billionN/A-20.81Analyst Report
Insmed logo
INSM
Insmed
1.2$32.62+3.1%$3.47 billion$136.47 million-12.55
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00+1.9%$3.46 billion$114.62 million-7.66Analyst Report
LEGN
Legend Biotech
1.2$26.00+0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.14+0.3%$3.39 billion$339.08 million-12.29Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.96+1.6%$3.39 billion$306.98 million-7.00
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87+1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54+1.3%$3.25 billion$36.13 million-69.46
Alkermes logo
ALKS
Alkermes
1.2$19.87+0.5%$3.16 billion$1.17 billion-43.19
Arvinas logo
ARVN
Arvinas
1.5$64.69+2.6%$3.16 billion$42.98 million-25.27
MorphoSys logo
MOR
MorphoSys
0.3$22.75+1.9%$3.05 billion$80.43 million108.34Decrease in Short Interest
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.60+4.2%$3.04 billionN/A-56.02Insider Selling
OPKO Health logo
OPK
OPKO Health
1.9$4.34+0.5%$2.91 billion$901.90 million-24.11
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.64+1.6%$2.89 billion$644.77 million-10.79
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07+5.2%$2.77 billion$421.03 million22.21Analyst Report
Insider Selling
News Coverage
Gap Up
Organogenesis logo
ORGO
Organogenesis
1.0$21.46+5.3%$2.75 billion$260.98 million-357.67
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.00+0.5%$2.71 billion$25 million-9.40Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.67+0.3%$2.71 billionN/A-23.99
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77+0.7%$2.67 billion$306.49 million25.58
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94+3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Xencor logo
XNCR
Xencor
1.2$42.78+4.4%$2.59 billion$156.70 million-30.56
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.88+1.1%$2.57 billion$2.11 million-8.85Analyst Report
Analyst Revision
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.22+3.6%$2.53 billion$60,000.00-9.70
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23+0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.76+3.6%$2.48 billion$15 million-17.68Unusual Options Activity
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.50+0.2%$2.42 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.57+2.6%$2.35 billion$33.94 million-88.91Gap Up
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.